{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pityriasis-versicolor/prescribing-information/oral-itraconazole/","result":{"pageContext":{"chapter":{"id":"95b98848-e241-56a6-b83d-380420c23440","slug":"oral-itraconazole","fullItemName":"Oral itraconazole","depth":2,"htmlHeader":"<!-- begin field 4772e837-ab67-4a5a-a3cd-a1ae1de9f227 --><h2>Oral itraconazole</h2><!-- end field 4772e837-ab67-4a5a-a3cd-a1ae1de9f227 -->","summary":"","htmlStringContent":"<!-- begin item cf00f012-0f6d-4b84-b132-5b44d7c021f9 --><!-- begin field 688c0f6e-045a-4637-aba4-ab791d42e873 --><!-- end field 688c0f6e-045a-4637-aba4-ab791d42e873 --><!-- end item cf00f012-0f6d-4b84-b132-5b44d7c021f9 -->","topic":{"id":"0fea6769-8496-527e-9900-49c0411410df","topicId":"c13665df-bfcd-4fcc-b476-7e462353856b","topicName":"Pityriasis versicolor","slug":"pityriasis-versicolor","lastRevised":"Last revised in April 2020","chapters":[{"id":"48061d3b-77de-5625-838f-3490efd16385","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a2b64334-2f3e-5682-a55c-d89347f8b48f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"ce5bd4c2-7fa7-58e8-83bd-614d945b9710","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"fd8be5be-8d54-5431-88b3-44c33e4401da","slug":"changes","fullItemName":"Changes"},{"id":"fc8f8e10-88b6-5879-a69c-18f87f3c8340","slug":"update","fullItemName":"Update"}]},{"id":"ef705ed5-a47f-528d-97cc-8d9af2963eb5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"5fdd92bc-0340-527b-8689-d48f307ce6e3","slug":"goals","fullItemName":"Goals"},{"id":"ec48d89c-955c-5e3d-af73-6e587354a56d","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ecafa7cb-70ed-551b-b6d1-ddcf4f6bed3d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"fd61e511-1bf0-541e-8192-19970ba59e82","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"05312c95-9379-5709-872d-b3e10aebfcc0","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b5911b4a-ad4b-52c9-9bfe-a0978bdc63c5","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"08f0e975-952b-5ec7-a211-0f0a447d63b6","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"d63e7392-070c-56c9-890f-bc58ae7b5b3a","slug":"definition","fullItemName":"Definition"},{"id":"1fbe5c19-2ec5-50c3-b69f-a251b7bfbd1c","slug":"causes","fullItemName":"Causes"},{"id":"2e638f9d-1d65-5294-9020-379452470ca9","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c223ff1b-62e0-5bc5-bb16-aee1037798a3","slug":"prognosis","fullItemName":"Prognosis"},{"id":"7e95bc3b-7443-5b1f-aa77-97a44859c0ee","slug":"complications","fullItemName":"Complications"}]},{"id":"5a3a3c2c-acb7-5f56-af38-2ddbcc543c8f","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"e5b4b862-ed72-5b87-88c3-cec73356d952","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"c0059764-1025-5915-ae2c-8a71310be239","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"9c584d50-0808-57d6-b5c7-cb1af47c1be2","fullItemName":"Management","slug":"management","subChapters":[{"id":"216757cf-4ca3-5974-b742-43171690f9df","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"05482fa5-1c4b-5f1b-8b8e-6137e274e4e5","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d7f1cba7-9069-572c-b52d-d9319951ed08","slug":"ketoconazole-2percent-shampoo","fullItemName":"Ketoconazole 2% shampoo"},{"id":"54569984-7427-54f7-b6cb-3522c344a0de","slug":"topical-imidazole-creams","fullItemName":"Topical imidazole creams"},{"id":"11062d95-1795-54d5-88e9-9c9d1464555e","slug":"selenium-sulphide-shampoo","fullItemName":"Selenium sulphide shampoo"},{"id":"ff895dc9-00a2-59b2-9e11-6529379ea8fd","slug":"oral-fluconazole","fullItemName":"Oral fluconazole"},{"id":"95b98848-e241-56a6-b83d-380420c23440","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"}]},{"id":"9d664332-8ca1-5c9d-a030-544c2adfea31","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5609556e-dbb4-56de-8035-bced2df7d533","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8e7f4e16-d4b6-59d4-919a-6eb3a9f60a94","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a652af6c-c591-5583-ba4e-0ce6cb952e3b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e7e76cf0-a6de-51cc-9a4b-89194241dc6d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d791c177-66f7-5aaa-ab09-a2079d32f854","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"12d54e36-6600-5446-83a4-05d3c235b7f0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f54e136f-01a7-5fed-a635-fa6f209d4e3f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"05482fa5-1c4b-5f1b-8b8e-6137e274e4e5","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"ba321bde-e622-5ee3-8384-1f2d6d912147","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 8069d2c0-9b3f-4800-887e-9d34d45036b2 --><h3>What are the contraindications and cautions for oral itraconazole?</h3><!-- end field 8069d2c0-9b3f-4800-887e-9d34d45036b2 -->","summary":"","htmlStringContent":"<!-- begin item cf8d5675-66ba-4a80-964a-7cdc5928b78d --><!-- begin field 6242d69f-5fcc-4d69-9a17-b9edbd7dd286 --><ul><li>Avoid oral itraconazole in:<ul><li>People with acute porphyria.</li><li>Pregnant or breastfeeding women.</li></ul></li><li>Avoid oral itraconazole or use with caution in: <ul><li>People with hepatic impairment, a history of hepatotoxicity with other drugs, or active liver disease. <ul><li>Liver function tests are not usually necessary for a course of treatment lasting less than 1 month, unless the person is taking concurrent hepatotoxic drugs, has a history of hepatotoxicity, or has hepatic impairment.</li><li>Advise the person to report signs of liver disease (such as anorexia, nausea and vomiting, fatigue, abdominal pain, or dark urine) and seek prompt medical attention.</li></ul></li></ul></li><li>Use oral itraconazole with caution in:<ul><li>Older adults.</li><li>People with cardiac disease and those being treated with negative inotropic drugs (such as calcium channel blockers).</li><li>People with chronic lung disease associated with pulmonary hypertension (including chronic obstructive pulmonary disease [COPD]).</li><li>People with HIV infection and neutropenia — absorption of itraconazole is reduced.</li><li>People with renal impairment — increased risk of heart failure and the bioavailability of oral itraconazole possibly reduced.</li><li>Women of childbearing age — ensure effective contraception during treatment and until the next menstrual period following end of treatment.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">BNF, 2020</a>]</p><!-- end field 6242d69f-5fcc-4d69-9a17-b9edbd7dd286 --><!-- end item cf8d5675-66ba-4a80-964a-7cdc5928b78d -->","subChapters":[]},{"id":"614b3ceb-abc3-5703-8bc6-466e2bed6f41","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 9d2a2818-e6ba-404f-848b-68b557379217 --><h3>What are the adverse effects of oral itraconazole?</h3><!-- end field 9d2a2818-e6ba-404f-848b-68b557379217 -->","summary":"","htmlStringContent":"<!-- begin item 6295ad70-d988-4d84-9f2c-f9e241f1636c --><!-- begin field ece1138f-3785-4848-9c80-90c4fabb9c17 --><ul><li>Adverse effects commonly include: <ul><li>Abdominal pain, nausea, constipation, diarrhoea, dyspnoea, hypokalaemia, headache, heart failure, oedema, skin reactions, and vision disorders.</li></ul></li><li>Rare cases of serious hepatotoxicity have been reported — advise the person to seek medical advice if they experience anorexia, vomiting, fatigue, abdominal pain, or dark urine.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">BNF, 2020</a>]</p><!-- end field ece1138f-3785-4848-9c80-90c4fabb9c17 --><!-- end item 6295ad70-d988-4d84-9f2c-f9e241f1636c -->","subChapters":[]},{"id":"f920adf8-b30e-527d-819c-fcd2e9b4881f","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 09f3e97b-230a-4907-8df9-5c209ce07622 --><h3>What are the drug interactions of oral itraconazole?</h3><!-- end field 09f3e97b-230a-4907-8df9-5c209ce07622 -->","summary":"","htmlStringContent":"<!-- begin item 270ca8f2-53b2-4bf2-80a0-043c576c2b2d --><!-- begin field becc7c09-d3ab-47b3-81eb-8aaab028af94 --><ul><li>Absorption of itraconazole is decreased when gastric acidity is reduced (for example by antacids, H2-receptor antagonists, or proton pump inhibitors).</li><li>Effect of itraconazole is reduced (due to cytochrome P450 CYP3A4 enzyme induction) by drugs such as carbamazepine, phenytoin, phenobarbital, rifampicin, and rifabutin — avoid concurrent use.</li><li>Antipsychotic drugs:<ul><li>Itraconazole is predicted to increase the exposure to pimozide, quetiapine, and sertindole, manufacturer advises avoidance.  </li><li>Itraconazole increases the concentration of haloperidol and risperidone, manufacturer advises caution/dose adjustment.</li></ul></li><li>Antiretroviral drugs — itraconazole increases the levels of most protease inhibitors, and itraconazole levels are increased by ritonavir and possibly indinavir. Manufacturer recommends avoiding concurrent use with nevirapine or efavirenz.</li><li>Calcium-channel blockers — monitor blood pressure control and heart rate, and for calcium-channel blocker adverse effects, particularly for felodipine. Itraconazole use with lercanidipine or nisoldipine is contraindicated by the manufacturer.</li><li>Disopyramide, ivabradine, mizolastine, and ranolazine — plasma levels of these drugs are increased by itraconazole, leading to an increased risk of arrhythmias.</li><li>Digoxin — monitor for signs of digoxin toxicity, and adjust the dose accordingly.</li><li>Ergotamine and methysergide — avoid concurrent use, owing to the increased risk of ergotism.  </li><li>Eletriptan — avoid concurrent use. Itraconazole increases eletriptan levels almost three-fold.</li><li>Eplerenone — itraconazole increases the bioavailability of eplerenone more than five-fold, avoid concurrent use</li><li>Phosphodiesterase type-5 inhibitors — ketoconazole markedly increases the levels of tadalafil, very markedly increases the levels of vardenafil, and may also increase the levels of sildenafil. Itraconazole is predicted to interact similarly — manufacturer advises use with caution or avoidance.</li><li>Statins — avoid concurrent use of simvastatin and atorvastatin with itraconazole.  </li><li>Other interactions include:<ul><li>Warfarin — itraconazole potentially increases the anticoagulant effect of warfarin, monitor the international normalized ratio (INR) closely.  </li><li>Ciclosporin — increases concentration of ciclosporin, manufacturer advises caution.</li><li>Reboxetine — the manufacturer advises that itraconazole should not be given with reboxetine.</li><li>Tacrolimus — monitor tacrolimus levels and adjust dose.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Baxter, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">BNF, 2020</a>]</p><!-- end field becc7c09-d3ab-47b3-81eb-8aaab028af94 --><!-- end item 270ca8f2-53b2-4bf2-80a0-043c576c2b2d -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}